Aseptic/Sterile Processing

Samsung Biologics Expands Manufacturing Facilities and Launches Cell Line Technology

August 13, 2020

The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.

Sorrel to Open a New Manufacturing Facility

July 07, 2020

The new site will offer initial design and development, low-volume manufacturing, and scalable high-quality production of wearable drug delivery devices.

Vetter and Rentschler Team Up for Strategic Collaboration

July 06, 2020

The agreement will combine Rentschler’s experience in drug substance manufacturing and Vetter’s expertise in aseptic fill/finish and secondary packaging.

Grand River Aseptic Manufacturing Opens Large-Scale Injectable Fill/Finish Facility

July 02, 2020

The new facility in Grand Rapids, MI, is part of the CDMO’s aggressive expansion plan.

Pall’s 24-Well Filter Plate Performs Cell Clarification and Sterilization

June 29, 2020

Pharmaceutical Technology's In the Lab eNewsletter

Pall has introduced a 24-well filter plate that can perform cell clarification and sterilization in one step.

Why Do Disinfectant Residues Matter?

June 02, 2020

Consider how to assess risks and understand possible sources of disinfectant residues in pharmaceutical manufacturing.

Ajinomoto Bio-Pharma Services, Humanigen in Manufacturing Agreement for COVID-19 Biologic

June 01, 2020

The companies have entered into a manufacturing agreement for the fill finish supply of lenzilumab for the potential treatment of COVID-19.

PharmTech Sponsored eBooks

Complications in Process Simulation Execution

June 01, 2020

Regulators have exaggerated expectations for simulated media fills.

PharmTech Sponsored eBooks

Minimizing Contamination During BioPharm R&D

June 01, 2020

The right approach to biological safety cabinets, and collaboration between engineers and those who will operate the equipment, is crucial to preventing cell-culture contamination.

BARDA Funds US-based Drug Manufacturing Initiative

May 19, 2020

HHS announces $354 million in funding for private industry to manufacture generic drugs in the US from raw materials to finished product.